Good day, and welcome to the Kingsway Q2 2024 earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If you wish to ask a question on today's call, you may press star one on your phone at any time. Please note, this conference is being recorded. With me on the call are J.T. Fitzgerald, Chief Executive Officer, and Kent Hansen, Chief Financial Officer. Before we begin, I want to remind everybody that today's conference may contain forward-looking statements. Forward-looking statements include statements regarding the future, including expected revenue, operating margins, expenses, and future business outlook. Actual results or trends could materially differ from those contemplated by those forward-looking statements. For a discussion of such risks and uncertainties, which could cause actual results to differ from those expressed or implied in the forward-looking statements, please see the risk factors detailed in the company's annual report on Form 10-K and subsequent Form 10-Qs and Form 8-Ks, filed with the Securities and Exchange Commission. Please note also that today's call may include the use of non-GAAP metrics that management utilizes to analyze the company's performance. A reconciliation of such non-GAAP metrics to the most comparable GAAP measures is available in the most recent press release, as well as in our periodic filings with the SEC. Now, I would like to turn the call over to J.T. Fitzgerald, CEO of Kingsway. J.T., please proceed. Thanks, Paul. Good afternoon, everyone, and welcome to the Kingsway earnings call for the Q2 of 2024. We had a solid quarter that was largely in line with our expectations. We saw improving performance in our extended warranty segment, which showed strong cash sales and moderating claims experience, and we exited the quarter with nice momentum heading into the back half of the year. Our KSX segment also performed well, with EBITDA improving sequentially and year over year. Additionally, this quarter has been marked by very positive deal-related activity. We have a couple of promising, high-quality prospects that we are working on, which, if completed, would significantly contribute to our growth trajectory moving forward. For the Q2 of 2024, consolidated revenue was $26.4 million, a modest increase of 1% compared to the prior year quarter, while consolidated Adjusted EBITDA was $2.4 million, a nice improvement over the $1.8 million in the year-ago quarter. For the extended warranty segment and the KSX segment, combined Adjusted EBITDA was $3.4 million in both the Q2 of this year and last year. In our extended warranty segment, the pricing adjustments that were implemented beginning in the second half of 2023 are having a positive impact in helping to offset claims expense, which increased only 2.9% over the prior year. You may recall that Q1 claims were 13.1% higher than last year. Also notably, our cash sales for the current quarter increased 4.6% over the prior year. Sequentially, adjusted EBITDA increased 12% from the Q1 of 2024, driven by higher earned revenue, a higher mix of extended warranty revenue at Trinity, and our ongoing focus on controlling costs. As we talked about during our last earnings call, the challenges faced by the businesses in extended warranty have moderated, and we feel that we hit an inflection point in the Q2. Turning to our search accelerator, or KSX segment, revenues increased 2% over prior year, primarily due to a favorable comparison resulting from the acquisitions of SPI and DDI in the second half of 2023. Ravix continues to perform both ahead of our original investment thesis and is trending nicely in 2024. The team at Ravix remains focused on increasing utilization rates, optimizing pricing, and disciplined cost management. While revenues were down in the quarter, gross margins continue to hold around 37%, a 200 basis point improvement over prior year. EBITDA was essentially flat year-over-year in the quarter. At C-Suite, the team is building a solid pipeline, and we continue to believe the business is headed in the right direction, despite persistently challenging market conditions. Revenue and adjusted EBITDA were lower in the Q2 compared to the prior year period. However, cost of sales and general and administrative expenses were also down from prior year. The pipeline of qualified new business opportunities looks strong, and the team is charting its course for accelerating revenue in the second half of 2024 and beyond. At SNS, for the Q2, revenue was flat sequentially, but both gross margin and Adjusted EBITDA improved due to a higher mix of travel nurse shifts in the current quarter. Gross margin was over 200 basis points better in Q2 than in Q1. Travel shifts increased 35.4% from the Q1, and the number of nurses on travel assignment, or TOA, has more than doubled since the beginning of the year. For the first time in a long while, the company exits the quarter with more TOA than at the same point last year. We continue to believe the longer-term outlook for the travel nurse market is promising. At Systems Products International, or SPI, the team delivered strong revenue and adjusted EBITDA in Q2, with revenues increasing 24% sequentially. The company has contracted with a number of new clients this year and is executing on its strategy to grow annual recurring revenue. Since acquisition, the company has grown ARR by 12%. At Digital Diagnostics Imaging, or DDI, revenue continues to be strong, increasing 14.6% over the prior year. EBITDA improved by 26.2% over the prior year period. To support its growth strategy and diversify its operational risk, DDI recently signed a new lease for a second operation center in Salt Lake City. We expect to have the location up and running in the second half of the year. The company continues to meet and exceed our original expectations. Based on the performance of our operating businesses, the 12-month run rate adjusted EBITDA remains at $16 million-$17 million. As a reminder, run rate is intended to capture the last 12 months of adjusted EBITDA for the businesses we currently own, including those we have recently acquired. Growth through acquisitions remains central to our corporate strategy, targeting opportunities that deliver predictably high returns on tangible capital in large and growing end markets. While the timing of completing transactions is challenging to predict, we are seeing a healthy level of activity related to potential transactions and believe we are on track to meet our target of 2-3 deals each year that can each generate $1 million-$3 million in annualized adjusted EBITDA. We currently have four highly talented Operators- in- Residence, or OIRs, who are actively searching for opportunities and are currently evaluating a number of attractive potential acquisition targets. In addition, we are actively recruiting new OIRs that can backfill and grow our bench of talent as our deal flow evolves. All in all, strong execution in the extended warranty businesses and continued progress against strategic objectives within our KSX businesses drove solid financial results for the Q2. I'll now turn the call over to Kent for some additional commentary related to our financials. Thanks, J.T. As a reminder, during the Q4 of 2022, we began executing a plan to sell one of our subsidiaries, VA Lafayette, which owns a medical clinic whose sole tenant is the U.S. Veterans Administration. As such, VA Lafayette is included in discontinued operations, and its assets and liabilities are reported as held for sale. The results of operations are reported separately and not included in the results reported today. Taking a look at our balance sheet and cash flows, at the end of the Q2 of 2024, we had cash and cash equivalents of $9.6 million, compared to $9.1 million at the end of 2023. Cash provided by operating activities from continuing operations was $500,000 for the first six months of 2024, compared to cash used in operating activities of $24.7 million in the year ago period. Cash used in the prior year was primarily due to outflows related to the payment of fees, expenses, and interest related to asset sales and debt repurchases, which was partially offset by operating income for the businesses in our operating segments. In May of this year, we amended our extended warranty loan to pay off all current extended warranty debt and replace it with a $1 million revolver, a term loan of $15 million, and a delayed draw loan of $6 million. Maturity date was extended to May of 2029. This amendment now gives us additional capacity to fund future acquisitions. As of June 30, 2024, we had a total outstanding debt, which is comprised of bank loans and subordinated debt of $47.3 million, compared to $44.4 million at the end of 2023. Net debt increased to $37.7 million as of June 30, 2024, compared to $35.3 million at the end of 2023, primarily due to the extended warranty amendment. In March of this year, our securities repurchase program was extended for one year through March of 2025. Year to date, we have repurchased 141,550 shares of common stock for an aggregate purchase price of approximately $1.1 million. Also of note, in July 2024, we completed the purchase of the minority 10% interest in IWS that we did not previously own, and as such, IWS is now a wholly owned subsidiary of the company. I'll now turn the call back over to Paul to open the line for any questions. Paul? Certainly. At this time, we'll be conducting a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. Once again, please press star one on your phone at this time if you wish to ask a question. Once again, that's star one on your phone at this time if you wish to ask a question. The first question today is coming from Adam Patinkin from David Capital. Adam, your line is live. Hey, guys. Thanks for taking my question today. I just wanted to ask quickly about the warranty business, if you don't mind. So I think that you gave a little bit of color that the cost inflation there has moderated pretty significantly, and I think, J.T., that you said it was up 2.9% year-over-year. Can you kind of provide a little bit more color there in terms of where your rates are trending relative to cost inflation and how you expect both of those to trend going forward over the duration of the year? ... Yeah. Hi, Adam. Thanks for the question. Yeah, so, warranty claims were up 2.9% or so in the quarter, mostly driven by severity, not frequency. As you know, we started taking rate back half of last year and into this year, and, you know, I think in the aggregate across the businesses, the sort of price increases were in the kind of high single digits. How much of that sticks and how much of that comes through in shifting mix and stuff is always a little bit hard to determine. But we're seeing probably about 4% or 5% of that come through in rate. And so, also, as you know, beginning in late Q2 and really in the Q3 of last year, we saw accelerating claims inflation, severity inflation, predominantly parts and labor. And so we're coming up against much easier comps in the second half of the year, for claims dollars. And so I would expect that year-over-year inflation will be much lower, and that rate that I mentioned will still continue to come through. Got it. That's really helpful. I appreciate it. Thank you, guys, and rooting for some of these acquisitions to come through that I, I know you're getting close on, or it sounds like you're getting close on. Appreciate it, guys. I'll go back in the queue. Thanks, Adam. Thank you. And once again, if there were any other questions at this time, please press star one on your phone. And there were no other questions from the lines. I'd now like to pass the call to James for some email questions. Thank you, operator. Yes, we did have two questions come in on email. The first one is, it says, "J.T., you said at the Investor Day, you were very happy with the two most recent acquisitions. Although they are recent, the reported numbers of both these businesses doesn't yet demonstrate their superior attributes and performance. Can you talk about why you still like these businesses, and how long before the performance starts to show up in the financials? Yeah. I, you know, I mentioned it a little bit in the prepared remarks. SPI, which we acquired in September of last year, vertical market software business, serving the fractional ownership, vacation property industry, has grown ARR since acquisition by roughly 12%. They've also added several new clients that they're in the process of onboarding, and so I would expect by the end of the year that we will have grown ARR by roughly 20% since inception. So I think that's really strong growth. You know, Drew has done a great job transitioning in there and is focused on investing in growing the number of new customers on their software platform. And so I think a little bit of that would be sacrificing a little bit of near-term profitability for growth in recurring revenue, you know, very high margin, recurring revenue, to go out and capture more market share in his addressable market. And then DDI, you know, as I mentioned, revenue in the quarter increased roughly 15% over the prior year, you know, prior to our ownership, and EBITDA improved even more dramatically. And so that financial performance is starting to come through in the financial statements, and it's just a really incredible opportunity here. Peter's doing a great job, really growing with the customers that he currently has, who are sending him more facilities to onboard. As I mentioned, in support of that growth and to create redundancy operationally and also tap a new labor pool for high quality EKG techs, we're opening a new facility in Salt Lake. So, yeah, I think we're really excited about the trajectory of both of those businesses. Excellent. And the last question, again, something you may have touched on in opening remarks, but maybe something to reinforce and reiterate. The question is: Are you seeing any signs of a turnaround in either C-Suite or the nursing business? What might, what facts might lead you to believe that better days are ahead for these two businesses? Yeah. You know, SNS, we'll start there. The nurse staffing business, you know, for the first time, we exit the quarter with more travelers on assignment than we had at the same point in time last year, so that's a great fact. And our TOA shifts in the quarter increased, you know, 35% over the Q1 of the year. And so Charles is doing a great job of recruiting nurses onto the platform and getting more TOA shifts, and so that's been really nice progress there. I think broadly, the industry is seeing gross margin compression start to abate and feels like we're kind of settling into a steady state. Always in the second half of the year, seasonally, there's more demand for travel and per diem nurses as hospital census increases during cold and flu season. So I think we're in a good position to capture that growing demand in the back half of the year. C-Suite, you know, it's you know, I mentioned that the challenges are a bit persistent. A lot of their business is recruiting for permanent placement of accounting staff at private equity portfolio companies. I think, you know, with some challenges around business optimism, people have been slow to hire. We've got a huge backlog of retained searches and as well as interim CFO work. It's getting people to pull the trigger and close those deals. I think Timmy's been really trying to push those along, and we're hopeful that the sentiment improves in the second half of the year. Still hard to tell, but he's been... You know, the backlog or pipeline of deals that he has is as strong as we've seen it. Great. Thank you, J.T. Operator, that's all from the questions on email. Okay, great. There were no other questions from the lines at this time. So would you like to conclude the call now? Yeah. Thanks, everyone. Have a great evening. Appreciate your participating on the call. Thank you. This does conclude today's conference. You may disconnect your lines at this time. Thank you for your participation.